A joint Korea Research Institute of Chemical Technology and Novartis AG patent describes antiviral 1,3-di-oxo-indene compounds reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, diabetes, hepatitis A, viral infection, myocarditis, myositis and pancreatitis, among others.
Aeovian Pharmaceuticals Inc. has prepared tricyclic fused imidazole compounds acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of neurodegeneration, inflammation, fibrosis, systemic scleroderma and more.
Researchers from North Carolina State University filed for protection of miniaturized, wireless, wound-monitoring sensors that may be incorporated into swabs or wound dressings for real-time, accurate assessment of wound status.
Gilead Sciences Inc. has synthesized 4-aminopyrrolo[2,1-F][1,2,4]triazine C-nucleoside analogues acting as prodrugs of GS-441524 and reported to be useful for the treatment of viral infections.
Arkuda Therapeutics Inc. has patented new fused tricyclic mucolipin-1 (MCOLN1; TRPML1) blockers reported to be useful for the treatment of cancer, liver diseases, amyotrophic lateral sclerosis, cardiovascular disorders, frontotemporal dementia, Alzheimer’s, Huntington’s and Parkinson’s disease.
Several recent Imhotex Ltd. patents describe novel analogues of muramyl dipeptide (MDP), desmuramylpeptides (DMPs), acting as nucleotide-binding oligomerization domain-containing protein 2 (NOD2) activators potentially useful for the treatment of Crohn’s disease.
Verge Analytics Inc. (dba Verge Genomics) has prepared and tested new hydrazone and pyrazole 3H-imidazo(4,5-b)pyridine compounds acting as 1-phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) inhibitors.
The first filing to emerge from Identifyher Ltd. seeks to gain protection for a wearable sensor that women can wear daily to track potential symptoms of perimenopause, providing them with data that can be used to find the right management plan for their needs.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented oxazolo[4,5-B]pyrazine and oxazolo[4,5-B]pyridine derivatives acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease and cardiovascular disorders.
RSS
